Terconazole for the treatment of vulvovaginal candidiasis.

Author(s): Thomason JL, Gelbart SM, Kellett AV, Scaglione NJ, Gotwalt KT, Broekhuizen FF

Affiliation(s): Department of Obstetrics and Gynecology, University of Wisconsin Medical School, Milwaukee 53201-0342.

Publication date & source: 1990-11, J Reprod Med., 35(11):992-4.

Publication type: Clinical Trial; Comparative Study ; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

A double-blind, randomized trial was conducted to evaluate the efficacy and safety of terconazole for vulvovaginal candidiasis. Treatment consisted of daily intravaginal application of one of the following regimens: 80-mg terconazole suppositories for 3 days, miconazole nitrate suppositories for 7 days or placebo suppositories for 7 days. The terconazole and miconazole nitrate groups had significantly higher therapeutic cure rates than did the placebo group. Evaluation of vaginal secretions with microscopic examination showed no evidence of leukocyte proliferation. Proline aminopeptidase activity, present in patients who have bacterial vaginosis, could not be detected in the vaginal secretions from patients with yeast vulvovaginitis.